Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Edaglitazone
Ro 205-2349 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| RO 205-2349 2 mg QD | EXPERIMENTAL | RO 205-2349 2 mg was taken once daily (QD) for 16 weeks during the double-blind treatment period. |
| RO 205-2349 5 mg QD | EXPERIMENTAL | RO 205-2349 5 mg was taken once daily (QD) for 16 weeks during the double-blind treatment period. |
| Name | Type | Description |
|---|---|---|
| RO 205-2349 | DRUG | - |
Inclusion Criteria: * Age 35 to 75 * Type 2 diabetes for longer than 3 months * HbA1c (glycosylated hemoglobin A1c) greater than 7.0% at screening * FPG (fasting plasma glucose) greater than 126 mg/dL at screening * BMI (body mass index) less than 40 kg/square meter Exclusion Criteria: * Type I d...
Ro 205-2349 is an investigational small molecule being developed for the treatment of diabetes, specifically type 2 diabetes mellitus. It is in Phase 2 clinical development and has been studied in patients with type 2 diabetes to evaluate its efficacy, safety, tolerability, and pharmacokinetics.
Ro 205-2349 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY on the OTC market.
Ro 205-2349 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 clinical trials have been completed, but the drug is not currently in active clinical trials.
Ro 205-2349 has been studied in two completed Phase 2 clinical trials. The first trial, NCT00057304, enrolled 190 patients with type 2 diabetes mellitus across multiple countries. The second trial, NCT00057317, also studied patients with type 2 diabetes mellitus in several countries.